Recent Updates
Recently added Catalysts

10x Genomics, Inc.

TXGFDA catalysts, PDUFA dates & pipeline intelligence
$55.09
▼ -3.1 · -5.33%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full TXG financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $15.1852W HIGH $102.81
Volume
1.94 M
Value Traded
107.72 M
Short % Float
10.63%
Days to Cover
4.1
-14.4%Week
-20.33%1 Month
-3.98%3 Month
+159.58%6 Month
-85.16%5 Year
-56.15%All Time

Cash Data

Unlock TXG cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
7.25 B
EPS (TTM)
-0.51
P/E Ratio
-
Ent. Value
6.78 B
Total Shares
131.53 M
Float Shares
117.35 M
Insiders
10.78%
Institutions
99.56%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every TXG catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

TXG Catalyst Timeline

Dated clinical, regulatory and corporate events for 10x Genomics, Inc.

Unlock the full TXG catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How TXG actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all TXG historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

No drug pipeline

10x Genomics, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.

Clinical Trial Results

Readouts, endpoints and source filings for every TXG program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every TXG trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock TXG insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Saxonov SergeDirector, Officer (Chief Executive Officer)Sell -31,000 1,019,249 held$62.90 11/10/2026
Unlock the full TXG insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
Casdin Capital, LLC 2 % (-45.9 %) 40.26 M 1.05 M -53.85% ( -1.23 M)
Unlock every fund holding TXG
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in TXG
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see TXG ownership
Insider and institutional ownership, quarter by quarter.

TXG Short Interest

Shares sold short, counted twice a month.

10.63%
Short % of Float
of tradable shares sold short
12.5M
Shares Sold Short
-2.0% vs prior count
4.1 Moderate
Days to Cover
trading days of normal volume to buy every short share back
3.0M
Avg Daily Volume
the average used for days to cover
Unlock TXG short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock TXG option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live TXG option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock TXG options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How TXG ranks across every disease it competes in

Competitive Position is a premium feature
See how TXG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

TXG News

TXG
Nov 10, 2026
TXGGeneral

Shanghai Precision Diagnostics and Fudan University Shanghai Cancer Center Launch Breast Cancer Biomarker Study Using 10x Genomics' Xenium Platform

10x Genomics announced a 24-month study in collaboration with Fudan University Shanghai Cancer Center and Shanghai Precision Diagnostics. The study aims to identify biomarkers that predict breast cancer patients' responses to neoadjuvant therapy. It will analyze tumor biopsy samples from 500 patients using the Xenium platform to enhance treatment personalization.

Read more →
TXG
Nov 5, 2026
TXGGeneral

10x Genomics Reports Third Quarter 2026 Financial Results

10x Genomics reported a revenue of $150.7 million for Q3 2026, marking a 1% increase from the previous year. The company successfully launched Atera, which has seen strong demand. Despite a gross margin improvement to 75%, 10x Genomics reported an operating loss of $16.1 million and a net loss of $19.4 million.

Read more →
TXG
Nov 2, 2026
TXGGeneral
▼ -12.1%on this newsshared move

10x Genomics Launches Sentira Single Cell, A New Agentic AI Experience for Chromium Analysis

10x Genomics launched Sentira Single Cell, a cloud-based AI application for analyzing Chromium data. This tool allows researchers to use natural language for inquiries, streamlining the path from questions to conclusions. Built on 10x Cloud, it offers scalable computing power and promotes independent data exploration. The application aims to democratize single cell research.

Read more →
TXG
Oct 27, 2026
TXGConferences/Events
▲ +7.2%on this news· ran to -21% by day 3shared move

10x Genomics to Participate in the 2026 Jefferies Global Healthcare Conference

10x Genomics announced its participation in the 2026 Jefferies Global Healthcare Conference. The management team will engage in a fireside chat on November 17 at 4:30 p.m. GMT. Interested parties can access a live webcast on the company's website, which will be available for replay for 30 days.

Read more →
TXG
Oct 13, 2026
TXGConferences/Events

10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026

10x Genomics, a leader in life science technology, will announce its third quarter financial results on November 5, 2026. The company will hold a public conference call to discuss these results and its business outlook. The financial results will be available on their website before the call, which will also be archived for later access.

Read more →
TXG
Oct 7, 2026
TXGGeneral
▼ -5.7%on this news

10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers

10x Genomics has announced a collaboration with Fred Hutch Cancer Center to enhance single cell and spatial technologies in cancer research. This initiative will focus on bladder cancer and acute myeloid leukemia, aiming to improve treatment response analysis and biomarker discovery. The partnership represents a significant step towards precision oncology.

Read more →
TXG
Sep 29, 2026
TXGGeneral

10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions

10x Genomics has launched Sentira, a new cloud analysis platform aimed at streamlining the analysis of complex biological data. The platform, starting with Sentira Spatial Analysis, significantly reduces data processing times, enabling researchers to reach experimental conclusions more rapidly. This innovation is expected to enhance the capabilities of researchers in spatial biology, especially with the integration of NVIDIA's accelerated computing.

Read more →
TXG
Sep 29, 2026
TXGGeneral

10x Genomics Begins Global Shipments of Atera, Putting Unprecedented Spatial Biology Capabilities in Researchers' Hands

10x Genomics has commenced global shipments of its Atera platform, which integrates advanced spatial biology capabilities. This innovative tool allows researchers to conduct comprehensive studies across various disease areas, including oncology and neurodegenerative diseases. The initial response has been overwhelmingly positive, with significant demand from leading research institutions and biopharma companies. Atera aims to transform biological research and drug discovery.

Read more →
TXG
Aug 28, 2026
TXGGeneral

10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences

10x Genomics won a patent infringement case against Parse Biosciences, with a jury ruling that Parse willfully infringed three patents licensed to Scale Biosciences. The jury awarded over $4.8 million in damages and rejected Parse's validity challenges. This decision underscores the significance of patent rights in fostering innovation in the life sciences sector.

Read more →
TXG
Aug 6, 2026
TXGGeneral
▲ +14.1%on this news· ran to +28% by day 1

10x Genomics Reports Second Quarter 2026 Financial Results

10x Genomics reported its second quarter 2026 financial results, revealing a revenue of $151 million, a 3% increase when excluding non-recurring revenue. The company acquired Proteintech Genomics to enhance its capabilities and announced collaborations with major research institutions. However, it faced an operating loss of $19.6 million and a net loss of $17.9 million, highlighting challenges despite revenue growth.

Read more →
TXG
Jul 29, 2026
TXGGeneral

10x Genomics and Lausanne University Hospital Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies for Cancer Care

10x Genomics has partnered with Lausanne University Hospital to enhance cancer diagnostics using single cell and spatial technologies. The collaboration aims to identify biomarkers that predict treatment responses across various cancer types. This multi-year study will analyze tumor samples from patients and integrate clinical outcomes to improve personalized treatment strategies.

Read more →
TXG
Jul 15, 2026
TXGConferences/Events

10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026

10x Genomics, a leader in life science technology, will report its second quarter 2026 financial results on August 6, 2026. The report will be followed by a public conference call at 1:30 PM PT to discuss the results and future outlook. The financial results will be available on the company's website prior to the call.

Read more →
TXG
Jun 17, 2026
TXGGeneral

10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer

10x Genomics has partnered with Cleveland Clinic to enhance diagnostic research for bladder cancer. This multi-year collaboration will utilize 10x's advanced platforms to analyze tumor samples from patients undergoing new therapies. The goal is to identify biomarkers that predict patient responses, improving treatment personalization in oncology.

Read more →
TXG
Jun 9, 2026
TXGGeneral

10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group

10x Genomics has acquired Proteintech Genomics to enhance its proteomics capabilities. This acquisition introduces the Human Discovery Panel, which allows integrated analysis of proteins and transcriptomic profiles. The move aligns with 10x's vision of advancing multiomic approaches in biological research. The transaction is not expected to significantly impact 10x's near-term financial outlook.

Read more →
TXG
May 7, 2026
TXGGeneral

10x Genomics Reports First Quarter 2026 Financial Results

10x Genomics reported its first quarter 2026 financial results, showing a 3% decrease in revenue to $150.8 million. However, excluding one-time revenues from the previous year, revenue increased by 9%. The company launched Atera, a new platform for spatial whole-transcriptome analysis, and ended the quarter with $539.8 million in cash. Despite a net loss of $13.5 million, the company remains optimistic about its growth trajectory.

Read more →
TXG
Apr 29, 2026
TXGConferences/Events
▼ -5.5%on this news

10x Genomics to Participate in the BofA Securities 2026 Healthcare Conference

10x Genomics, a leader in single cell and spatial biology, will participate in the BofA Securities 2026 Healthcare Conference on May 13. The management team will engage in a fireside chat, which will be available via a live webcast. This event highlights the company's commitment to advancing human health through innovative research solutions.

Read more →
TXG
Apr 20, 2026
TXGGeneral
▼ -5.7%on this news· ran to -18% by day 3

10x Genomics Introduces Atera, a New Platform to Redefine How Biology is Measured and Understood

10x Genomics has launched Atera, a new platform for whole-transcriptome spatial biology analysis, offering single-cell sensitivity at scale. Debuting at the AACR Annual Meeting 2026, Atera aims to redefine biological measurement by overcoming previous limitations in spatial technologies. The platform has garnered interest from major research institutions and is expected to enhance understanding of complex biological systems.

Read more →
TXG
Apr 15, 2026
TXGConferences/Events

10x Genomics to Report First Quarter 2026 Financial Results on May 7, 2026

10x Genomics, a leader in single cell and spatial biology, will report its financial results for Q1 2026 on May 7, 2026. The company plans to hold a public conference call to discuss these results and future business developments. The financial news release will be available on their website prior to the call.

Read more →
TXG
Feb 5, 2026
TXGGeneral
▼ -7.1%on this news

PharosAI and 10x Genomics Partner to Transform Cancer Research with AI and Spatial Biology

10x Genomics has partnered with PharosAI to develop a comprehensive multimodal cancer dataset using AI and spatial biology. This initiative, supported by UK government funding, aims to enhance early diagnosis and precision therapies. The collaboration will initially focus on breast cancer, expanding to other types, and will make datasets accessible to researchers globally.

Read more →
TXG
Jan 23, 2026
TXGConferences/Events

10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

10x Genomics, a leader in single cell and spatial biology, will report its financial results for Q4 and the full year 2025 on February 12, 2026. The announcement includes a public conference call for analysts and investors to discuss the results and future outlook. The financial results will be available on the company's website prior to the call.

Read more →

About 10x Genomics, Inc.

Pleasanton, CA 1,178 employees 10xgenomics.com
Headquarters6230 STONERIDGE MALL ROAD, PLEASANTON, CA, 94588
BIOPHARMAWATCH ELITE
Trade the next TXG catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime